news

Fujifilm to launch rapid antigen COVID-19 test in Europe

8
SHARES

Having received the CE certificate, Fujifilm can now launch its highly-sensitive, rapid antigen test kit for SARS-CoV-2 in Europe.

Box with a series of silver packages in - one pulled out is labelled 'SARS-CoV-2 RAPID ANTIGEN TEST'

FUJIFILM Europe GmbH has received the CE certificate for its antigen test kit for the diagnosis of SARS-CoV-2 infection and can now launch the product in Europe. SARS-CoV-2 is the virus that causes COVID-19.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

The test is based on the company’s proprietary silver amplification immunochromatography method, based on silver amplification technology used in the photo-developing process, that the enterprise has leveraged in rapid diagnostic testing equipment and reagents for influenza and other infectious diseases previously. According to Fujifilm, since 2011, the system has been adopted by several medical institutes in Japan as a high-sensitivity antigen test capable of detecting viruses even when viral load is low at the onset of a disease.

The company said in a statement that the new testing kit can rapidly and sensitively examine the presence of SARS-CoV-2 antigens in specimens, detecting the virus at an early stage and in view of a relatively low viral load, with results delivered within 10-13 minutes. The rapid antigen test uses nasopharyngeal swab samples and can be performed within the community as well as clinical settings.

Mr Masaharu Fukumoto, Senior Vice President FUJIFILM Europe GmbH Medical Systems Division, commented: “During the pandemic Fujifilm supported the global healthcare community in the complex management of the emergency. It did so through its diagnostic and IT/AI solutions so that COVID-19 patients could be treated with the utmost care and precision. Today we can provide further support for the early detection of COVID-19, through a rapid antigen test that can provide a highly sensitive result for early detection. We used our proprietary silver amplification immunochromatographic method, that amplifies signal particles more than 100 times and increases the sensitivity and has the potential to enhance detection in more asymptomatic patients carrying the COVID-19 virus an at an early stage.”

Related organisations

Related people

Related diseases & conditions

,

Share via
Share via